GVM±R in Patients With Relapsed or Refractory Aggressive NHL

Exclusion Criteria

• •1. The subject had previously received any of the following anti-tumor treatments:
• •1. Subjects who have been treated with mitoxantrone or mitoxantrone liposomes;
• •2. Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin was more than 360 mg/m2 (1 mg doxorubicin equivalent to 2 mg epirubicin);
• •3. Subjects who received anti-tumor treatment (including chemotherapy, targeted therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received trial drugs within 4 weeks before the first administration of the study drugs;
• •4. Subjects who received autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation within 100 days of the first administration of study drugs;
• •2. Hypersensitivity to any study drug or its components;
• •3. Uncontrolled systemic diseases (such as active infection, uncontrolled hypertension, diabetes, etc.)
• •4. Heart function and disease meet one of the following conditions:
• •1. Long QTc syndrome or QTc interval \> 480 ms;
• •2. Complete left bundle branch block, grade II or III atrioventricular block;
• •3. Serious and uncontrolled arrhythmias requiring drug treatment;
• •4. New York Heart Association grade ≥ III;
• •5. Cardiac ejection fraction (LVEF)# 50%;
• •6. A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment.
• •9\. Hepatitis B and hepatitis C active infection (defined as hepatitis B virus surface antigen positive and hepatitis B virus DNA higher than 1x103 copy/mL; hepatitis C virus RNA high than 1x103 copy/mL) 10. Human immunodeficiency virus (HIV) infection (defined as HIV antibody positive) 11. Patients with other malignant tumors, except for effectively controlled non- melanoma skin basal cell carcinoma, breast/cervical carcinoma in situ or other tumors without treatment during the past 5 years. 12. Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures; 13. Unsuitable subjects for this study determined by the investigator.